The Protein Brewery recently secured €30 million in Series B funding, shortly after its mycelium ingredient, Fermotein, became the first novel mycoprotein to receive EU Novel Food approval. The €30 million Series B funding, announced by AgFunderNews and FoodBev, positions Fermotein as a significant player among emerging plant-based protein sources for 2026. The approval from the European Union validates a new class of alternative proteins, marking a critical moment for the company's expansion plans.
The alternative protein market has long relied on established sources like soy and pea, but a novel fungal protein has just achieved significant regulatory and financial breakthroughs, challenging the status quo. Significant regulatory and financial breakthroughs for a novel fungal protein indicate a shift in consumer and investor interest towards more diversified and sustainably produced protein options beyond traditional plant-based offerings. The tension between entrenched ingredients and innovative alternatives is now more pronounced.
Mycelium-based proteins are likely to capture a substantial and rapidly growing share of the alternative protein market, driving further innovation and diversification in the food industry. Fermotein's unique nutritional profile and its validated regulatory pathway support this trajectory, setting a new standard for what novel ingredients can achieve. The market is increasingly seeking alternatives that offer both nutritional completeness and environmental advantages.
1. Fermotein's Comprehensive Nutritional Profile
Fermotein contains approximately 50% complete protein with all essential amino acids, according to Food Ingredients First. The 50% complete protein content, comparable to animal proteins, provides a robust nutritional foundation for various food applications. The presence of all essential amino acids ensures that Fermotein can serve as a primary protein source in diets, addressing concerns about nutritional adequacy often associated with some plant-based alternatives.
Furthermore, this mycelium ingredient also contains 30% fiber, a significant amount that contributes to digestive health and satiety. The combination of high complete protein and substantial fiber positions Fermotein as a nutritionally comprehensive alternative that could surpass the functional benefits of many existing plant-based proteins. Consumers are increasingly seeking ingredients that offer multiple health benefits beyond just protein content.
Fermotein also features unique fungal bioactives, which may offer additional health advantages not typically found in conventional protein sources. The unique fungal bioactives are derived from The Protein Brewery’s proprietary fungal strain, as reported by FoodBev, ensuring a consistent and controlled production process. The rich composition of complete protein, high fiber, and unique bioactives, derived from a proprietary fungal strain, offers a superior nutritional and functional profile compared to many existing alternatives. The rich composition of complete protein, high fiber, and unique bioactives makes Fermotein an attractive ingredient for product developers aiming to create more nutritious and functional food products.
2. Pioneering Regulatory Success and Market Entry
Fermotein is derived from Rhizomucor pusillus fungal protein, a detail highlighted by Food Ingredients First. Fermotein's specific fungal origin underscores its novelty in the alternative protein sector. The ingredient's unique biological source required rigorous evaluation to secure regulatory authorization.
The Protein Brewery’s Fermotein is the first novel mycoprotein ingredient of its kind to gain regulatory authorization in the EU, a distinction noted by Food Ingredients First. The precision in regulatory classification is significant; while Cultivated X states Fermotein is the first approved mycelium ingredient in the EU, Food Ingredients First specifies it as the first *novel mycoprotein ingredient of its kind*. The novelty specifically applies to its unique fungal protein type, highlighting a more precise regulatory classification and setting a new benchmark for what constitutes truly innovative and approved alternative proteins.
The €30 million Series B funding, directly following Fermotein's EU Novel Food approval, signals that regulatory validation for truly novel protein sources is now a primary driver for significant investment, challenging the long-held perception that market traction must precede major capital infusions. The immediate financial backing, coupled with its regulatory success, demonstrates a clear path for Fermotein's global commercialization and adoption. The Protein Brewery is launching Fermotein with several US customers in the coming months, according to FoodBev and BOM, indicating an aggressive market entry strategy. Rapid globalization, leveraging its EU regulatory breakthrough, could rapidly diversify the alternative protein landscape and put pressure on companies relying solely on traditional protein sources.
| Feature | Fermotein (by The Protein Brewery) |
|---|---|
| Regulatory Status | Received EU Novel Food approval; first novel mycoprotein ingredient of its kind to gain regulatory authorization in the EU; first approved mycelium ingredient in the EU |
| Protein Content | Approximately 50% complete protein (with all essential amino acids) |
| Fiber Content | 30% fiber |
| Fungal Strain | Derived from Rhizomucor pusillus fungal protein |
| Protein Yield vs. Meat/Soy/Pea | Yields 26 times more protein than meat, five times more than soy, and four times more than peas, according to Green Queen |
| Resource Use vs. Beef | Uses 1% of the land, 5% of the water, and releases 3% of the emissions compared to beef, as reported by Green Queen |
| Capital Intensity | Production process is significantly less capital-intensive, according to Green Queen |
| US Market Entry | Launching with several US customers in the coming months |
| EU Market Entry | Expected to launch in the EU in Q3 2026 |
| Anticipated Supply | Anticipates supplying 600 metric tons in 2027, increasing to over 2,000 tons by 2029, according to Green Queen |
3. The Broader Impact of Mycelium Innovation
Fermotein mycoprotein received EU approval under the Novel Food Regulation, as reported by AgFunderNews. The Novel Food Regulation framework is designed to ensure the safety of novel food ingredients before they reach the market, making this approval a critical endorsement of mycelium's viability. The rigorous process involved in gaining this authorization underscores the scientific scrutiny Fermotein has undergone.
The Protein Brewery has also received European Commission authorization to sell its mycelium ingredient Fermotein, a direct confirmation from Cultivated X. Dual regulatory validation under the stringent Novel Food Regulation and direct authorization from the European Commission solidifies mycelium's position as a commercially viable and scalable protein source. Such comprehensive approval paves the way for wider industry adoption and integration into mainstream food products. The establishment of this regulatory precedent is crucial for other novel protein developers.
Fermotein's comprehensive nutritional profile — 50% complete protein, 30% fiber, and unique fungal bioactives — combined with its first-of-its-kind EU approval, establishes a new, higher bar for what 'next-generation' alternative proteins must deliver to compete effectively against established plant-based options. Fermotein's comprehensive nutritional profile and first-of-its-kind EU approval demonstrate that innovation in alternative proteins is moving beyond mere replication of existing products towards ingredients that offer enhanced nutritional and functional benefits. The success of Fermotein suggests that regulatory milestones for truly novel protein sources are now primary drivers for significant investment and market penetration.
4. Frequently Asked Questions
What are the newest plant-based protein alternatives?
Beyond traditional soy and pea, the newest plant-based protein alternatives include novel ingredients like mycelium, microalgae, and various fermented biomasses. Novel ingredients like mycelium, microalgae, and various fermented biomasses often offer distinct nutritional profiles, improved sustainability metrics, and unique textural properties compared to their predecessors. Companies are investing heavily in research and development to bring these diverse proteins to market, expanding consumer choices.
Are there plant proteins better than soy and pea?
Yes, some emerging plant proteins offer unique advantages that can be considered 'better' depending on specific nutritional or functional goals. Fermotein, for example, is a high-protein, high-fiber ingredient, according to BOM, which provides a complete amino acid profile alongside significant dietary fiber and fungal bioactives. This combination of attributes.mprehensive profile can surpass the functional benefits of many existing plant-based proteins, offering a more nutritionally complete and versatile option for food manufacturers and consumers.
What are the benefits of novel plant proteins?
Novel plant proteins offer a range of benefits, including enhanced nutritional completeness, improved sustainability credentials, and diversified allergen profiles. Many new proteins, like mycelium, require significantly less land and water than animal agriculture and even some traditional crops. They also introduce new textures and flavors, allowing for greater innovation in food product development and catering to a wider array of dietary needs and preferences.
